Publication

Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis

Synbad Study Grp, van der Aa, L. B., van Aalderen, W. M. C., Heymans, H. S. A., Smitt, J. H. S., Nauta, A. J., Knippels, L. M. J., Ben Amor, K. & Sprikkelman, A. B., Feb-2011, In : Allergy. 66, 2, p. 170-177 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Synbiotics prevent asthma-like symptoms in infants withatopic dermatitis

    Final publisher's version, 393 KB, PDF document

DOI

  • Synbad Study Grp
  • L. B. van der Aa
  • W. M. C. van Aalderen
  • H. S. A. Heymans
  • J. Henk Sillevis Smitt
  • A. J. Nauta
  • L. M. J. Knippels
  • K. Ben Amor
  • A. B. Sprikkelman

P>Background:

Infants with atopic dermatitis (AD) have a high risk of developing asthma. We investigated the effect of early intervention with synbiotics, a combination of probiotics and prebiotics, on the prevalence of asthma-like symptoms in infants with AD.

Methods:

In a double-blind, placebo-controlled multicentre trial, ninety infants with AD, age <7 months, were randomized to receive an extensively hydrolyzed formula with Bifidobacterium breve M-16V and a galacto/fructooligosaccharide mixture (Immunofortis (R)), or the same formula without synbiotics during 12 weeks. After 1 year, the prevalence of respiratory symptoms and asthma medication use was evaluated, using a validated questionnaire. Also, total serum IgE and specific IgE against aeroallergens were determined.

Findings:

Seventy-five children (70.7% male, mean age 17.3 months) completed the 1-year follow-up evaluation. The prevalence of 'frequent wheezing' and 'wheezing and/or noisy breathing apart from colds' was significantly lower in the synbiotic than in the placebo group (13.9%vs 34.2%, absolute risk reduction (ARR) -20.3%, 95% CI -39.2% to -1.5%, and 2.8%vs 30.8%, ARR -28.0%, 95% CI -43.3% to -12.5%, respectively). Significantly less children in the synbiotic than in the placebo group had started to use asthma medication after baseline (5.6%vs 25.6%, ARR -20.1%, 95% CI -35.7% to -4.5%). Total IgE levels did not differ between the two groups. No children in the synbiotic and five children (15.2%) in the placebo group developed elevated IgE levels against cat (ARR -15.2%, 95% CI -27.4% to -2.9%).

Conclusion:

These results suggest that this synbiotic mixture prevents asthma-like symptoms in infants with AD.

Original languageEnglish
Pages (from-to)170-177
Number of pages8
JournalAllergy
Volume66
Issue number2
Publication statusPublished - Feb-2011
Externally publishedYes

    Keywords

  • asthma, prebiotics, prevention, probiotics, synbiotics, PLACEBO-CONTROLLED TRIAL, RANDOMIZED-CONTROLLED-TRIAL, ALLERGIC AIRWAY RESPONSE, DOUBLE-BLIND, YOUNG-CHILDREN, ORAL TREATMENT, MURINE MODEL, FOLLOW-UP, PROBIOTICS, PREVALENCE

ID: 71334503